Biosimilar filgrastim in autologous peripheral blood hematopoietic stem cell mobilization and post-transplant hematologic recovery

Francesco Marchesi, Andrea Mengarelli

Research output: Contribution to journalArticlepeer-review

Abstract

To date, two kinds of Granulocyte Colony-Stimulating Factors (G-CSF) have been approved for autologous peripheral blood hematopoietic stem cell (PBSCs) mobilization and posttransplant hematologic recovery after high-dose chemotherapy: filgrastim (originator and biosimilar) and lenograstim. Biosimilar filgrastim has been approved on the basis of comparable efficacy and safety in clinical studies where it has been used as chemotherapy-induced febrile neutropenia prophylaxis, but no specific pre-registration studies have been published in the transplant setting. Hence, there is still general skepticism about the role of biosimilar G-CSFs in this setting of patients. This review of biochemical, pre-clinical and clinical data suggests significant comparability of biosimilar filgrastim with both originator filgrastim and lenograstim in autologous PBSCs mobilization and post-autograft hematologic recovery.

Original languageEnglish
Pages (from-to)2217-2229
Number of pages13
JournalCurrent Medicinal Chemistry
Volume23
Issue number21
DOIs
Publication statusPublished - Jun 1 2016

Keywords

  • Autologous stem cell transplant
  • Biosimilar filgrastim
  • Hematologic recovery
  • Lenograstim
  • Originator filgrastim
  • Peripheral blood hematopoietic stem cell mobilization

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Biosimilar filgrastim in autologous peripheral blood hematopoietic stem cell mobilization and post-transplant hematologic recovery'. Together they form a unique fingerprint.

Cite this